Hot Pursuit     04-Jul-23
Biocon subsidiary launches biosimilar for Humira in US
Biocon Biologics Ltd (BBL), a subsidiary of Biocon, has launched HULIO (adalimumab-fkjp) injection, a biosimilar to Humira (adalimumab), in the United States.
The drug is a monoclonal antibody used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis.

HULIO is available at two price points: 5% below the current Humira list price and approximately 85% below the current Humira list price.

HULIO meets the rigorous biosimilar approval standards of the FDA. Like Humira, HULIO is citrate-free and is made without natural rubber latex.

Biocon Biologics also offers HULIO360, a robust patient support program, which includes benefits verification and prior authorization support, copay assistance, a bridge program for eligible patients, and at-home nurse injection training.

"The launch of HULIO, our biosimilar adalimumab, in the United States is an important milestone for Biocon Biologics as it expands our well-known biosimilar product offering to patients in the United States. This launch builds on our strong presence in oncology and diabetes and re-affirms our commitment to enabling affordable access to biologics,” said Shreehas Tambe, CEO & managing director, Biocon Biologics.

"Biocon Biologics is pleased to make HULIO, a patient-friendly, 2-click, prefilled pen available in the United States for patients with certain inflammatory diseases. There are no buttons to push. Patients remove the cap and push the device against their skin to trigger their injection. Designed and built with patients in mind, healthcare professionals and patients don't have to miss a beat with HULIO; they simply, 'Click, Click, Go,'" said Mathew Erick, chief commercial officer of advanced markets, Biocon Biologics.

Biocon Biologics is a fully integrated, global biosimilars company committed to transforming healthcare and transforming lives by enabling affordable access to high quality biosimilars for millions of patients worldwide.

Biocon is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

Biocon reported 31% rise in consolidated net profit to Rs 313 crore on a 57% increase in revenue from operations to Rs 3,774 crore in Q4 FY23 over Q4 FY22.

The scrip fell 0.81% to settle at Rs 263.40 on Monday, 3 July 2023.

Previous News
  Benchmarks trade falt; oil & gas shares rally for 9th day in row
 ( Market Commentary - Mid-Session 24-May-24   12:33 )
  Market at day’s high; VIX climbs 3.96%; realty shares advance
 ( Market Commentary - Mid-Session 18-Apr-24   12:37 )
  Biocon
 ( Results - Analysis 17-May-24   10:41 )
  Biocon Ltd spurts 1.22%, gains for third straight session
 ( Hot Pursuit - 07-Jun-24   13:05 )
  Biocon signs exclusive licensing and supply agreement with Handok
 ( Corporate News - 24-May-24   09:06 )
  Biocon Ltd up for third consecutive session
 ( Hot Pursuit - 01-Dec-23   13:05 )
  Biocon jumps after inking pact with Biomm SA
 ( Hot Pursuit - 18-Apr-24   11:47 )
  Biocon’s Andhra Pradesh facility gets 3 USFDA observations
 ( Hot Pursuit - 15-Jun-24   16:32 )
  Biocon Ltd soars 3.74%, rises for third straight session
 ( Hot Pursuit - 02-Jan-24   13:05 )
  Biocon update on subsidiary's biologics license application for Insulin-R product
 ( Corporate News - 07-Jan-23   12:33 )
  Biocon gains as arm takes over Viatris' biosimilar biz in over 70 countries
 ( Hot Pursuit - 06-Jul-23   12:03 )
Other Stories
  Lemon Tree launches its first property in Jharkhand
  16-Jul-24   08:50
  Waaree Renewable gains on bagging solar project
  15-Jul-24   15:49
  HDFC Life Q1 PAT climbs 15% YoY to Rs 478 cr
  15-Jul-24   15:45
  HDFC AMC hits record high after Q1 PAT rises 26% YoY to Rs 604 cr in FY25
  15-Jul-24   15:36
  Shipping Corporation of India Ltd leads losers in 'A' group
  15-Jul-24   15:00
  Bank of Maharashtra rallies after Q1 PAT climbs 46% YoY to Rs 1,293 cr in FY25
  15-Jul-24   14:49
  Mishtann Foods drops after Q1 PAT grows 3.4% YoY
  15-Jul-24   14:48
  Sheetal Cool Products Ltd leads losers in 'B' group
  15-Jul-24   14:45
  Volumes spurt at Godfrey Phillips India Ltd counter
  15-Jul-24   14:30
  MTNL hits 52-week high on appointing Ravi A Robert as the CMD
  15-Jul-24   14:18
Back Top